Lisa Situ
@lisasitu.bsky.social
Assistant Editor at Cancer Discovery, published by AACR.
BBS Harvard PhD '24 and proud UCLA Bruin.
Views are my own.
Link to sign up for Cancer Discovery News alerts: https://aacrjournals.org/pages/alerts
BBS Harvard PhD '24 and proud UCLA Bruin.
Views are my own.
Link to sign up for Cancer Discovery News alerts: https://aacrjournals.org/pages/alerts
RAF-independent MEK1-mutant Histiocytoses Respond to ERK Inhibition
A #ResearchWatch summary of a recent study by
Eli L. Diamond, Omar Abdel-Wahab, Benjamin H. Durham and colleagues @mskcancercenter.bsky.social
A #ResearchWatch summary of a recent study by
Eli L. Diamond, Omar Abdel-Wahab, Benjamin H. Durham and colleagues @mskcancercenter.bsky.social
RAF-independent MEK1-mutant Histiocytoses Respond to ERK Inhibition
Major Finding: RAF-independent MEK activation promotes histiocytic neoplasms that are sensitive to ERK inhibition.Concept: MEK1E102_I103del drives myelomonocytic expansion, hepatosplenomegaly, and an ...
aacrjournals.org
December 12, 2025 at 5:55 PM
RAF-independent MEK1-mutant Histiocytoses Respond to ERK Inhibition
A #ResearchWatch summary of a recent study by
Eli L. Diamond, Omar Abdel-Wahab, Benjamin H. Durham and colleagues @mskcancercenter.bsky.social
A #ResearchWatch summary of a recent study by
Eli L. Diamond, Omar Abdel-Wahab, Benjamin H. Durham and colleagues @mskcancercenter.bsky.social
Out today: Molecular Residual Disease Precedes Disease-Free Survival Events by Months, a #ResearchWatch summary of an impactful exploratory post hoc analysis of the ADAURA trial by Dr. Roy Herbst, Dr. Thomas John, Dr. Yi-Long Wu, and colleagues
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Molecular Residual Disease Precedes Disease-Free Survival Events by Months
Major Finding: Molecular residual disease (MRD) preceded death or clinical recurrence in the ADAURA trial by nearly 5 months. Concept: Longitudinal MRD monitoring may stratify risk for patients with E...
aacrjournals.org
June 12, 2025 at 2:41 PM
Out today: Molecular Residual Disease Precedes Disease-Free Survival Events by Months, a #ResearchWatch summary of an impactful exploratory post hoc analysis of the ADAURA trial by Dr. Roy Herbst, Dr. Thomas John, Dr. Yi-Long Wu, and colleagues
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
ICYMI: Ascites-derived Lipid Uptake Drives NK Cell Dysfunction in Ovarian Cancer, a #ResearchWatch summary of a new study by @karen--s.bsky.social, @lydialynch.bsky.social, and colleagues at @ludwigcancer.bsky.social @princetonmolbio.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Ascites-derived Lipid Uptake Drives NK Cell Dysfunction in Ovarian Cancer
Major Finding: Lipids derived from ascites are taken up by NK cells and drive NK cell dysfunction in ovarian cancer.
Concept: Polar lipids such as phosphatidylcholine disrupt NK plasma membrane order ...
aacrjournals.org
June 11, 2025 at 4:29 PM
ICYMI: Ascites-derived Lipid Uptake Drives NK Cell Dysfunction in Ovarian Cancer, a #ResearchWatch summary of a new study by @karen--s.bsky.social, @lydialynch.bsky.social, and colleagues at @ludwigcancer.bsky.social @princetonmolbio.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
ICYMI: SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity, a #ResearchWatch summary of a new study by Dr. Bo Li, @liliyanglab.bsky.social, and colleagues at @dgsomucla.bsky.social @uclastemcell.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity
Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8+ T-cell antitumor immunity.Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor immunity ...
aacrjournals.org
June 11, 2025 at 4:24 PM
ICYMI: SSRIs Elevate Intratumoral Serotonin and Enhance Antitumor Immunity, a #ResearchWatch summary of a new study by Dr. Bo Li, @liliyanglab.bsky.social, and colleagues at @dgsomucla.bsky.social @uclastemcell.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Out today: Cholesterol Metabolism Dictates Secondary Organ Colonization in Pancreatic Cancer, a #ResearchWatch summary of a new study by Dr. Gilles Rademaker, @rushika-perera.bsky.social, and colleagues at @ucsanfrancisco.bsky.social 🧬
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Cholesterol Metabolism Dictates Secondary Organ Colonization in Pancreatic Cancer
Major Finding: PCSK9 regulates cholesterol uptake and controls the trajectory of metastasis to secondary organs in pancreatic ductal adenocarcinoma (PDAC). Concept: Cholesterol uptake supports mTORC1-...
aacrjournals.org
June 11, 2025 at 4:02 PM
Out today: Cholesterol Metabolism Dictates Secondary Organ Colonization in Pancreatic Cancer, a #ResearchWatch summary of a new study by Dr. Gilles Rademaker, @rushika-perera.bsky.social, and colleagues at @ucsanfrancisco.bsky.social 🧬
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
ICYMI: "Patient-Specific Hematologic Setpoints Inform Diagnosis and Prognosis" - a #ResearchWatch summary of a study by Brody Foy, John M. Higgins, and colleagues @uwdeptmedicine.bsky.social @harvardmed.bsky.social #MassGeneralBrigham
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Patient-Specific Hematologic Setpoints Inform Diagnosis and Prognosis
Main Findings: Complete blood count indices are patient-specific and stable over decades in healthy adults.Concept: These hematologic setpoints are deep physiological phenotypes associated with variat...
doi.org
February 13, 2025 at 3:47 PM
ICYMI: "Patient-Specific Hematologic Setpoints Inform Diagnosis and Prognosis" - a #ResearchWatch summary of a study by Brody Foy, John M. Higgins, and colleagues @uwdeptmedicine.bsky.social @harvardmed.bsky.social #MassGeneralBrigham
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Cancer Discovery #ResearchWatch: Digoxin Reduces Circulating Tumor Cell Cluster Size in #BreastCancer, a summary of the study by Christian Kurzeder, Bich Doan Nguyen-Sträuli, Ilona Krol, Alexander Ring, Marcus Vetter, Nicola Aceto, et al @ethzurich.bsky.social @unibas.ch
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Digoxin Reduces Circulating Tumor Cell Cluster Size in Breast Cancer
Major Finding: Digoxin treatment reduces circulating tumor cell cluster size in patients with metastatic breast cancer.Concept: Genes involved in cell–cell adhesion and cell cycle pathways are suppres...
doi.org
February 13, 2025 at 3:42 PM
Cancer Discovery #ResearchWatch: Digoxin Reduces Circulating Tumor Cell Cluster Size in #BreastCancer, a summary of the study by Christian Kurzeder, Bich Doan Nguyen-Sträuli, Ilona Krol, Alexander Ring, Marcus Vetter, Nicola Aceto, et al @ethzurich.bsky.social @unibas.ch
doi.org/10.1158/2159...
doi.org/10.1158/2159...
ICYMI: "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours" - a #ResearchWatch summary of a study by Ignacio Melero, Eugen Leo, and colleagues #ClinicaNavarra #CIMA_unav #visugromab #CatalYm
doi.org/10.1158/2159...
doi.org/10.1158/2159...
GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition
Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance that ...
doi.org
February 11, 2025 at 3:09 PM
ICYMI: "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours" - a #ResearchWatch summary of a study by Ignacio Melero, Eugen Leo, and colleagues #ClinicaNavarra #CIMA_unav #visugromab #CatalYm
doi.org/10.1158/2159...
doi.org/10.1158/2159...
🧪Read this week's Cancer Discovery #ResearchWatch: The Immune Evasin Nef Augments Allogeneic #CART Function and Survival, a summary of the study by Karlo Perica, Michel Sadelain, and colleagues @mskcancercenter.bsky.social @mskdeptofmed.bsky.social
doi.org/10.1158/2159...
doi.org/10.1158/2159...
The Immune Evasin Nef Augments Allogeneic CAR T Function and Survival
Major Finding: HIV Nef expression reduces allorecognition and apoptotic cell death of CAR T cells.Concept: Controlled Nef expression reduces HLA-I levels and protects CAR T cells from CD8+ T cell– and...
doi.org
February 11, 2025 at 3:07 PM
🧪Read this week's Cancer Discovery #ResearchWatch: The Immune Evasin Nef Augments Allogeneic #CART Function and Survival, a summary of the study by Karlo Perica, Michel Sadelain, and colleagues @mskcancercenter.bsky.social @mskdeptofmed.bsky.social
doi.org/10.1158/2159...
doi.org/10.1158/2159...
🧪Read today's #ResearchWatch: A Pediatric Pan-Cancer Cohort Enables the Study of Systemic Antitumor Immunity, a summary of a 📃by Qi Chen, Binbin Zhao, Ziyang Tan, Linda Ljungblad, @petterbrodin.bsky.social, et al @imperialcollegeldn.bsky.social @ki.se aacrjournals.org/cdnews/news/...
A Pediatric Pan-Cancer Cohort Enables the Study of Systemic Antitumor Immunity
Major Finding: An analysis of immune responses in children with cancer reveals the effects of age and tumor type. Concept: Pediatric tumors have varied mutational burden which correlates with immune c...
aacrjournals.org
February 7, 2025 at 8:45 PM
🧪Read today's #ResearchWatch: A Pediatric Pan-Cancer Cohort Enables the Study of Systemic Antitumor Immunity, a summary of a 📃by Qi Chen, Binbin Zhao, Ziyang Tan, Linda Ljungblad, @petterbrodin.bsky.social, et al @imperialcollegeldn.bsky.social @ki.se aacrjournals.org/cdnews/news/...
Reposted by Lisa Situ
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG
Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...
aacrjournals.org
January 28, 2025 at 6:48 PM
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
Read this week's Cancer Discovery #ResearchWatch: Cancer Cells Induce T-Cell Dysfunction Through Mitochondrial Transfer, a summary of the study by Hideki Ikeda, Yosuke Togashi, and colleagues at Okayama University
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Cancer Cells Induce T-Cell Dysfunction Through Mitochondrial Transfer
Major Finding: Cancer cells transfer mitophagy-resistant mitochondria to tumor-infiltrating lymphocytes (TIL) that impair antitumor activity. Concept: Deubiquitinase USP30 protects cancer cell-derived...
doi.org
February 7, 2025 at 2:59 PM
Read this week's Cancer Discovery #ResearchWatch: Cancer Cells Induce T-Cell Dysfunction Through Mitochondrial Transfer, a summary of the study by Hideki Ikeda, Yosuke Togashi, and colleagues at Okayama University
doi.org/10.1158/2159...
doi.org/10.1158/2159...
🧬 #ResearchWatch: Loss–Translocation–Amplification #Chromothripsis Drives #Osteosarcoma Evolution, a summary of the study by @jevalleinclan.bsky.social, Solange De Noon, Adrienne Flanagan, Isidro Cortes-Ciriano, and colleagues @ucl.ac.uk @ebi.embl.org @uclnews.bsky.social
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Loss–Translocation–Amplification Chromothripsis Drives Osteosarcoma Evolution
Main Finding: High-grade osteosarcomas frequently exhibit a loss–translocation–amplification (LTA) pattern of chromothripsis that inactivates TP53 and amplifies oncogenes.Concept: Ongoing chromothrips...
doi.org
February 6, 2025 at 5:00 PM
🧬 #ResearchWatch: Loss–Translocation–Amplification #Chromothripsis Drives #Osteosarcoma Evolution, a summary of the study by @jevalleinclan.bsky.social, Solange De Noon, Adrienne Flanagan, Isidro Cortes-Ciriano, and colleagues @ucl.ac.uk @ebi.embl.org @uclnews.bsky.social
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Cancer Discovery #ResearchWatch: High-risk ER+ #BreastCancers Genomically Resemble HER2+ Tumors, a summary of the study by @khoulahan.bsky.social, @lisemangiante.bsky.social, @crissotomayor.bsky.social, @alvinahere.bsky.social, @cncurtis.bsky.social + colleagues @ Stanford
doi.org/10.1158/2159...
doi.org/10.1158/2159...
High-risk ER+ Breast Cancers Genomically Resemble HER2+ Tumors
Main Finding: HER2+ breast tumors and high-risk ER+ breast tumors share genomic features that reflect similar mechanisms of tumor evolution.Concept: The genomic architecture of breast cancer is constr...
doi.org
February 6, 2025 at 2:42 PM
Cancer Discovery #ResearchWatch: High-risk ER+ #BreastCancers Genomically Resemble HER2+ Tumors, a summary of the study by @khoulahan.bsky.social, @lisemangiante.bsky.social, @crissotomayor.bsky.social, @alvinahere.bsky.social, @cncurtis.bsky.social + colleagues @ Stanford
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Congratulations on these exciting results, Nick and team! We were very happy to feature the work! #ResearchWatch
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG
Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...
aacrjournals.org
January 28, 2025 at 7:42 PM
Congratulations on these exciting results, Nick and team! We were very happy to feature the work! #ResearchWatch
How do barrier tissues promote repair and regeneration without tipping the ⚖️ toward malignant transformation?
Find out in today's #ResearchWatch summary of a recent 📜 by Srustidhar Das, S. Martina Parigi, Xinxin Luo, Eduardo J. Villablanca, and colleagues.
aacrjournals.org/cdnews/news/...
Find out in today's #ResearchWatch summary of a recent 📜 by Srustidhar Das, S. Martina Parigi, Xinxin Luo, Eduardo J. Villablanca, and colleagues.
aacrjournals.org/cdnews/news/...
The Liver X Receptor Axis Balances Intestinal Regeneration and Tumorigenesis
Major Finding: The liver X receptor (LXR) pathway drives intestinal regeneration and limits tumorigenesis.Concept: Transcriptomic and pharmacologic studies define a CYP27A1–LXR–TLS signaling axis in i...
aacrjournals.org
December 5, 2024 at 4:08 PM
How do barrier tissues promote repair and regeneration without tipping the ⚖️ toward malignant transformation?
Find out in today's #ResearchWatch summary of a recent 📜 by Srustidhar Das, S. Martina Parigi, Xinxin Luo, Eduardo J. Villablanca, and colleagues.
aacrjournals.org/cdnews/news/...
Find out in today's #ResearchWatch summary of a recent 📜 by Srustidhar Das, S. Martina Parigi, Xinxin Luo, Eduardo J. Villablanca, and colleagues.
aacrjournals.org/cdnews/news/...
Out today: Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive #BladderCancer, a #ResearchWatch summary of recent clinical findings by Roger Li, James J. Mulé, Jose R. Conejo-Garcia, and colleagues.
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer
Major Finding: A phase 1b trial demonstrated the safety of cretostimogene grenadenorepvec plus nivolumab in muscle-invasive bladder cancer (MIBC).Concept: Boosting immune checkpoint inhibition with on...
aacrjournals.org
December 4, 2024 at 4:00 PM
Out today: Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive #BladderCancer, a #ResearchWatch summary of recent clinical findings by Roger Li, James J. Mulé, Jose R. Conejo-Garcia, and colleagues.
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Countdown to #ASH24! Are you heading to San Diego this weekend? If so, I'd love to connect! If you're presenting, please let me know - I want to hear about your work!
December 2, 2024 at 6:24 PM
Countdown to #ASH24! Are you heading to San Diego this weekend? If so, I'd love to connect! If you're presenting, please let me know - I want to hear about your work!
Last week in Cancer Discovery News: GD2-CAR T-cell Therapy is Safe in H3K27M+ Diffuse Midline Glioma, a #ResearchWatch summary of promising clinical findings by Michelle Monje, Sneha Ramakrishna, Crystal Mackall, and colleagues.
doi.org/10.1158/2159...
doi.org/10.1158/2159...
GD2-CAR T-cell Therapy is Safe in H3K27M+ Diffuse Midline Glioma
Main Finding: A phase I clinical trial demonstrates the safety of GD2-targeted CAR T-cell therapy in H3K27M+ diffuse midline glioma.Concept: H3K27M+ diffuse midline gliomas express high levels of GD2,...
doi.org
December 2, 2024 at 6:13 PM
Last week in Cancer Discovery News: GD2-CAR T-cell Therapy is Safe in H3K27M+ Diffuse Midline Glioma, a #ResearchWatch summary of promising clinical findings by Michelle Monje, Sneha Ramakrishna, Crystal Mackall, and colleagues.
doi.org/10.1158/2159...
doi.org/10.1158/2159...
ICYMI: "APOBEC3-Mediated Mutations Promote CCND1 ecDNA Biogenesis in Bladder Cancer," a #ResearchWatch summary of recent findings by Duy D. Nguyen, William F. Hooper, Weisi Liu, Olivier Elemento, @nicorobine.bsky.social, Bishoy M. Faltas, and colleagues.
doi.org/10.1158/2159...
doi.org/10.1158/2159...
APOBEC3-Mediated Mutations Promote CCND1 ecDNA Biogenesis in Bladder Cancer
Major Finding: APOBEC3-associated mutagenesis and ecDNA formation coordinately drive urothelial cancer evolution.Concept: ecDNA events enable adaptive resistance to chemotherapy.Impact: This study del...
doi.org
November 27, 2024 at 3:09 PM
ICYMI: "APOBEC3-Mediated Mutations Promote CCND1 ecDNA Biogenesis in Bladder Cancer," a #ResearchWatch summary of recent findings by Duy D. Nguyen, William F. Hooper, Weisi Liu, Olivier Elemento, @nicorobine.bsky.social, Bishoy M. Faltas, and colleagues.
doi.org/10.1158/2159...
doi.org/10.1158/2159...
ICYMI: "Epigenetic Regulation of T-Cell Differentiation Mediates Immunotherapy Response," a #ResearchWatch summary of recent findings from Tae Gun Kang, Ben Youngblood, Caitlin Zebley, and colleagues.
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Epigenetic Regulation of T-Cell Differentiation Mediates Immunotherapy Response
Major Finding: ASXL1 regulates T-cell terminal differentiation and exhaustion during chronic antigen exposure.Concept: Disruption of ASXL1 alters histone ubiquitination to promote a stem-like effector...
doi.org
November 27, 2024 at 2:48 PM
ICYMI: "Epigenetic Regulation of T-Cell Differentiation Mediates Immunotherapy Response," a #ResearchWatch summary of recent findings from Tae Gun Kang, Ben Youngblood, Caitlin Zebley, and colleagues.
doi.org/10.1158/2159...
doi.org/10.1158/2159...
Hello, hello! Very happy to see so many familiar faces over yonder. I’m excited to continue connecting and to receive my daily dose of excellent science! 🤗🔬🧬
November 26, 2024 at 10:39 PM
Hello, hello! Very happy to see so many familiar faces over yonder. I’m excited to continue connecting and to receive my daily dose of excellent science! 🤗🔬🧬
Reposted by Lisa Situ
Follow Cancer Discovery News for breaking updates and Research Watch summaries! Visit the homepage aacrjournals.org/cdnews and sign up for email alerts aacrjournals.org/pages/alerts!
November 20, 2024 at 5:04 PM
Follow Cancer Discovery News for breaking updates and Research Watch summaries! Visit the homepage aacrjournals.org/cdnews and sign up for email alerts aacrjournals.org/pages/alerts!